Please login to the form below

Not currently logged in
Email:
Password:

Element of Pfizer's Viagra patent rejected

The US Patent and Trademark Office has partially rejected Pfizer's patent claim on Viagra due to similarities to a Chinese herb

An appeals board within the US Patent and Trademark Office has partially rejected Pfizer's patent claim on its erectile dysfunction drug, Viagra (sildenafil), ruling that an element of the drug was not significantly different to the Chinese medicine, Yin Yang Huo (Horny Goat Weed), and did not represent a new invention.

In coming to its conclusion on the ruling, the appeals board stated that the patent claim was the next logical step up from using Yin Yang Huo in the treatment of erectile dysfunction. A chemical ingredient of the herb was found to be similar to an enzyme inhibitor found in Viagra.

The claim formed part of a 2002 lawsuit filed by Pfizer against Eli Lilly over its rival drug, Cialis. Pfizer has until April 12, to seek a rehearing or appeal against the decision.

The patent in question is due to expire in 2019. This ruling only concerns one element of Viagra, and Pfizer could therefore still use the patent to block generic competition from the duplication of the drug's active ingredient (sildenafil citrate).

Pfizer's revenue for 2009 included $1.89bn from the sale of Viagra.

17th February 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics